An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst (2009) 1.31

Effective incorporation of biomarkers into phase II trials. Clin Cancer Res (2009) 1.17

Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes. J Biopharm Stat (2012) 0.89

A review of phase II trial designs for initial marker validation. Contemp Clin Trials (2013) 0.80

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One (2016) 0.76

An optimal stratified Simon two-stage design. Pharm Stat (2016) 0.75

An adaptive design for updating the threshold value of a continuous biomarker. Stat Med (2016) 0.75

An efficient basket trial design. Stat Med (2017) 0.75

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol (2010) 1.98

Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg (2005) 1.71

Endpoints for agents that slow tumor growth. Contemp Clin Trials (2006) 1.52

Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist (2008) 1.11

Application of a facial injury severity scale in craniomaxillofacial trauma. J Oral Maxillofac Surg (2006) 0.97

Comparison of the severity of bilateral Le Fort injuries in isolated midface trauma. J Oral Maxillofac Surg (2005) 0.80

Abstracts from the American Association Of Oral And Maxillofacial Surgeons annual scientific meeting: proportion published and time to publication. J Oral Maxillofac Surg (2005) 0.77